Greater Los Angeles Clinical Center of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer

慢性胰腺炎、糖尿病和胰腺癌研究联盟大洛杉矶临床中心

• 批准号: 10447160
• 负责人: Mark Goodarzi
• 金额: $ 50.71万
• 依托单位: CEDARS-SINAI MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10447160
• 关键词: Adult; Ancillary Study; Area; Artificial Intelligence; Biological Assay; California; Cancer Detection; Child; Childhood; Chronic Phase; Clinical; Clinical Management; Clinical Research; Clinical Treatment; Clinical Trials; Clinical Trials Data Monitoring Committees; Cohort Studies; Collaborations; Complex; County; Development; Diabetes Mellitus; Diagnosis; Diagnostic; Early Diagnosis; Enzymes; Exocrine pancreas; Exocrine pancreatic insufficiency; Functional disorder; Future; Genetic Predisposition to Disease; Goals; Health system; Healthcare Systems; Human; Institutes; Leadership; Los Angeles; Malignant neoplasm of pancreas; Medical center; Methods; Modeling; Morbidity - disease rate; National Cancer Institute; National Institute of Diabetes and Digestive and Kidney Diseases; Natural History; Non-Insulin-Dependent Diabetes Mellitus; Pancreatic Diseases; Pancreatic Ductal Adenocarcinoma; Pancreatic enzyme; Pancreatitis; Pathogenicity; Patients; Pharmacologic Substance; Principal Investigator; Public Health; Recurrence; Research; Research Personnel; Resources; Risk Factors; Role; Series; Site; Techniques; United States; United States National Institutes of Health; Universities; X-Ray Computed Tomography; acute pancreatitis; base; blood glucose regulation; chronic pancreatitis; clinical center; design; disorder risk; epidemiology study; ethnic diversity; imaging modality; liquid biopsy; novel; novel diagnostics; organizational structure; participant retention; predictive modeling; premalignant; recruit; response; study population; treatment trial; working group

This is an application for renewal of Clinical Center designation of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). The Greater Los Angeles Clinical Center has provided considerable leadership in the organization and progress of the CPDPC. Dr. Pandol serves as co-chair of the Steering Committee and Dr. Goodarzi co-chairs the Type 3c Working Group. We have excelled in recruitment and retention of participants in the cohort studies implemented through the CPDPC designed to elucidate the natural history and develop means of diagnosis, treatment and clinical management of chronic pancreatitis (CP) and its complications in children and adults, and to determine the pathogenic interrelationships of diabetes and pancreatic cancer and develop the means of early diagnosis and management of pancreatic cancer. In addition, we have been performing a number ancillary and associated studies to support the overall goals of CPDPC, including: 1. Epidemiologic studies defining risk factors for pancreatic cancer and the natural history of CP; 2. Determining that genetic susceptibility for type 2 diabetes is a strong risk factor for diabetes associated with CP; 3. Developing liquid biopsy assays for aiding in the diagnosis of pancreatic cancer and CP; 4. Investigating mechanisms of pancreatitis and pancreatic cancer for rational pharmaceutical treatments; and 5. Conducting pilot clinical trials for treatment of recurrent acute and chronic pancreatitis. For the next phase of the CPDPC we are committed to the following Specific Aims: 1. Continue recruitment and retention of subjects in CPDPC cohort studies (PROCEED, INSPPIRE 2, NOD, DETECT) in existing and additional study sites, as well as increase diversity in the study population. 2. Continue currently supported ancillary studies to further develop risk factor models combined with liquid biopsy assays for early diagnosis of chronic pancreatitis and pancreatic cancer, and advance mechanism- based treatments and clinical trials for recurrent acute and chronic pancreatitis and pancreatic cancer. 3. Build models that combine clinical features with genetic susceptibility to allow the prediction of future development of diabetes in patients with chronic pancreatitis. 4. Determine the role of pancreatic enzyme replacement in regulating glucose homeostasis in patients with chronic pancreatitis and diabetes, with or without pancreatic exocrine insufficiency. 5. Use existing and annotated pre-diagnostic CT scans to develop artificial intelligence-based techniques for highly sensitive and specific methods for CT-based early pancreatic cancer detection. Our Center involves Cedars-Sinai Medical Center, UCLA Medical Center, the VA Greater Los Angeles Healthcare System and the University of Southern California/Los Angeles Public Health System with an organizational structure designed to expand recruitment into cohort studies of CPDPC with increased diversity and to facilitate our participation in ancillary studies.

这是续签财团临床中心指定的申请 胰腺炎，糖尿病和胰腺癌（CPDPC）。大洛杉矶临床中心提供了 CPDPC的组织和进步方面的领导能力很大。 Pandol博士担任 指导委员会和Goodarzi博士共同主席3C型工作组。我们在招聘方面表现出色 并保留通过CPDPC实施的队列研究中的参与者，旨在阐明 自然病史和发展慢性胰腺炎（CP）诊断，治疗和临床管理的手段 及其在儿童和成人中的并发症，并确定糖尿病和 胰腺癌并发展了胰腺癌早期诊断和管理的手段。此外， 我们一直在进行一项辅助和相关研究，以支持CPDPC的整体目标， 包括：1。定义胰腺癌危险因素和CP自然史的流行病学研究； 2。 确定2型糖尿病的遗传易感性是与CP相关的糖尿病的强大危险因素。 3。开发液体活检测定法以帮助诊断胰腺癌和CP诊断； 4。调查 胰腺炎和胰腺癌的机制，用于理性药物治疗；和5。进行 试验临床试验，用于治疗复发性急性和慢性胰腺炎。对于CPDPC的下一阶段我们 致力于以下具体目标： 1。继续招募和保留CPDPC队列研究中的受试者（继续进行，insppire 2，nod， 在现有研究地点和其他研究地点中检测），并增加研究人群的多样性。 2。继续支持的辅助研究，以进一步发展危险因素模型与液体结合 活检测定于慢性胰腺炎和胰腺癌的早期诊断，并提高机制 基于复发性急性和慢性胰腺炎和胰腺癌的基于基于的治疗和临床试验。 3。建立将临床特征与遗传敏感性相结合的模型，以允许对未来的预测 慢性胰腺炎患者糖尿病的发展。 4。确定胰酶替代在调节患者中葡萄糖稳态中的作用 慢性胰腺炎和糖尿病，有或没有胰腺外分泌功能不全。 5。使用现有和注释的诊断前CT扫描来开发基于人工智能的技术 基于CT的早期胰腺癌检测的高度敏感和特定方法。 我们的中心涉及加州大学洛杉矶分校医疗中心的雪松西奈医学中心，弗吉尼亚州大洛杉矶 医疗保健系统和南加州大学/洛杉矶公共卫生系统 组织结构旨在将招聘扩大到CPDPC的队列研究，并增加多样性 并促进我们参与辅助研究。